BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 37738504)

  • 1. Mass Spectrometry-Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine.
    Joshi SK; Piehowski P; Liu T; Gosline SJC; McDermott JE; Druker BJ; Traer E; Tyner JW; Agarwal A; Tognon CE; Rodland KD
    Annu Rev Pharmacol Toxicol; 2024 Jan; 64():455-479. PubMed ID: 37738504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Precision oncology from a proteogenomics perspective].
    Huang Y; Wu S; Shu K; Zhu Y
    Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3616-3627. PubMed ID: 36305397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification.
    Fu S; Liu X; Luo M; Xie K; Nice EC; Zhang H; Huang C
    Expert Rev Proteomics; 2017 Apr; 14(4):351-362. PubMed ID: 28276747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteogenomics: From next-generation sequencing (NGS) and mass spectrometry-based proteomics to precision medicine.
    Ang MY; Low TY; Lee PY; Wan Mohamad Nazarie WF; Guryev V; Jamal R
    Clin Chim Acta; 2019 Nov; 498():38-46. PubMed ID: 31421119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer proteogenomics: current impact and future prospects.
    Mani DR; Krug K; Zhang B; Satpathy S; Clauser KR; Ding L; Ellis M; Gillette MA; Carr SA
    Nat Rev Cancer; 2022 May; 22(5):298-313. PubMed ID: 35236940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical potential of mass spectrometry-based proteogenomics.
    Zhang B; Whiteaker JR; Hoofnagle AN; Baird GS; Rodland KD; Paulovich AG
    Nat Rev Clin Oncol; 2019 Apr; 16(4):256-268. PubMed ID: 30487530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A proteogenomics data-driven knowledge base of human cancer.
    Liao Y; Savage SR; Dou Y; Shi Z; Yi X; Jiang W; Lei JT; Zhang B
    Cell Syst; 2023 Sep; 14(9):777-787.e5. PubMed ID: 37619559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of clinical proteogenomics in lung cancer.
    Nishimura T; Nakamura H; Végvári Á; Marko-Varga G; Furuya N; Saji H
    Expert Rev Proteomics; 2019 Sep; 16(9):761-772. PubMed ID: 31402712
    [No Abstract]   [Full Text] [Related]  

  • 9. Proteogenomic interrogation of cancer cell lines: an overview of the field.
    Tsang O; Wong JWH
    Expert Rev Proteomics; 2021 Mar; 18(3):221-232. PubMed ID: 33877947
    [No Abstract]   [Full Text] [Related]  

  • 10. Methods, Tools and Current Perspectives in Proteogenomics.
    Ruggles KV; Krug K; Wang X; Clauser KR; Wang J; Payne SH; Fenyö D; Zhang B; Mani DR
    Mol Cell Proteomics; 2017 Jun; 16(6):959-981. PubMed ID: 28456751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteogenomics in Nephrology: A New Frontier in Nephrological Research.
    Chavali K; Coker H; Youngblood E; Karaduta O
    Curr Issues Mol Biol; 2024 May; 46(5):4595-4608. PubMed ID: 38785547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frontiers in mass spectrometry-based clinical proteomics for cancer diagnosis and treatment.
    Haga Y; Minegishi Y; Ueda K
    Cancer Sci; 2023 May; 114(5):1783-1791. PubMed ID: 36661476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Connecting Proteomics to Next-Generation Sequencing: Proteogenomics and Its Current Applications in Biology.
    Low TY; Mohtar MA; Ang MY; Jamal R
    Proteomics; 2019 May; 19(10):e1800235. PubMed ID: 30431238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated proteo-genomic approach for early diagnosis and prognosis of cancer.
    Shukla HD; Mahmood J; Vujaskovic Z
    Cancer Lett; 2015 Dec; 369(1):28-36. PubMed ID: 26276717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteogenomics: Key Driver for Clinical Discovery and Personalized Medicine.
    Barbieri R; Guryev V; Brandsma CA; Suits F; Bischoff R; Horvatovich P
    Adv Exp Med Biol; 2016; 926():21-47. PubMed ID: 27686804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteogenomic data and resources for pan-cancer analysis.
    Li Y; Dou Y; Da Veiga Leprevost F; Geffen Y; Calinawan AP; Aguet F; Akiyama Y; Anand S; Birger C; Cao S; Chaudhary R; Chilappagari P; Cieslik M; Colaprico A; Zhou DC; Day C; Domagalski MJ; Esai Selvan M; Fenyö D; Foltz SM; Francis A; Gonzalez-Robles T; Gümüş ZH; Heiman D; Holck M; Hong R; Hu Y; Jaehnig EJ; Ji J; Jiang W; Katsnelson L; Ketchum KA; Klein RJ; Lei JT; Liang WW; Liao Y; Lindgren CM; Ma W; Ma L; MacCoss MJ; Martins Rodrigues F; McKerrow W; Nguyen N; Oldroyd R; Pilozzi A; Pugliese P; Reva B; Rudnick P; Ruggles KV; Rykunov D; Savage SR; Schnaubelt M; Schraink T; Shi Z; Singhal D; Song X; Storrs E; Terekhanova NV; Thangudu RR; Thiagarajan M; Wang LB; Wang JM; Wang Y; Wen B; Wu Y; Wyczalkowski MA; Xin Y; Yao L; Yi X; Zhang H; Zhang Q; Zuhl M; Getz G; Ding L; Nesvizhskii AI; Wang P; Robles AI; Zhang B; Payne SH;
    Cancer Cell; 2023 Aug; 41(8):1397-1406. PubMed ID: 37582339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia.
    Pino JC; Posso C; Joshi SK; Nestor M; Moon J; Hansen JR; Hutchinson-Bunch C; Gritsenko MA; Weitz KK; Watanabe-Smith K; Long N; McDermott JE; Druker BJ; Liu T; Tyner JW; Agarwal A; Traer E; Piehowski PD; Tognon CE; Rodland KD; Gosline SJC
    Cell Rep Med; 2024 Jan; 5(1):101359. PubMed ID: 38232702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology.
    Ji S; Feng L; Fu Z; Wu G; Wu Y; Lin Y; Lu D; Song Y; Cui P; Yang Z; Sang C; Song G; Cai S; Li Y; Lin H; Zhang S; Wang X; Qiu S; Zhang X; Hua G; Li J; Zhou J; Dai Z; Wang X; Ding L; Wang P; Gao D; Zhang B; Rodriguez H; Fan J; Clevers H; Zhou H; Sun Y; Gao Q
    Sci Transl Med; 2023 Jul; 15(706):eadg3358. PubMed ID: 37494474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-cancer proteogenomics characterization of tumor immunity.
    Petralia F; Ma W; Yaron TM; Caruso FP; Tignor N; Wang JM; Charytonowicz D; Johnson JL; Huntsman EM; Marino GB; Calinawan A; Evangelista JE; Selvan ME; Chowdhury S; Rykunov D; Krek A; Song X; Turhan B; Christianson KE; Lewis DA; Deng EZ; Clarke DJB; Whiteaker JR; Kennedy JJ; Zhao L; Segura RL; Batra H; Raso MG; Parra ER; Soundararajan R; Tang X; Li Y; Yi X; Satpathy S; Wang Y; Wiznerowicz M; González-Robles TJ; Iavarone A; Gosline SJC; Reva B; Robles AI; Nesvizhskii AI; Mani DR; Gillette MA; Klein RJ; Cieslik M; Zhang B; Paulovich AG; Sebra R; Gümüş ZH; Hostetter G; Fenyö D; Omenn GS; Cantley LC; Ma'ayan A; Lazar AJ; Ceccarelli M; Wang P;
    Cell; 2024 Feb; 187(5):1255-1277.e27. PubMed ID: 38359819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic and genomic profiling of pancreatic cancer.
    Ansari D; Torén W; Zhou Q; Hu D; Andersson R
    Cell Biol Toxicol; 2019 Aug; 35(4):333-343. PubMed ID: 30771135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.